Zopiclone Market 2026 forecast predicts growth due to emerging technology
Zopiclone is a cyclopyrrolone that belongs to a family of psychotherapeutic agents used to treat insomnia. It is sold as a tablet. It functions as a GABA agonist, blocking signal propagation through nerves in the brain. As a result, zopiclone has a soothing effect on the user, which increases their sleep cycle. (Learn about the Zopiclone Market Growth Forecast)
Imovane, Zimovane, and Dopareel are brand names for zopiclone, a nonbenzodiazepine hypnotic agent used to relieve insomnia. The market for zopiclone is very fragmented. Although core competitors continue to accelerate innovation and, in certain cases, digital transitions, market leaders, as well as new entrants with niche products, dominate the overall competitive landscape.
This article discusses the current business situation and how it is expected to improve in the future. This study explores growth determinants, micro and macroeconomic factors, prospects, technologies, and main industry patterns that are expected to have a significant effect on the global Zopiclone market growth by 2026.
Zopiclone Market Analysis by Region
The pandemic has reshaped the Zopiclone industry. The way the supply-side of the market is accessed, the market ecosystem has moved in one direction. The Zopiclone market is new to North America, Europe, Asia-Pacific, the Middle East, and Africa, as well as Latin America, due to its geographical orientation. Global businesses are seeking to spread their goods and services through various continents. Furthermore, procurements and affiliations with some of the most prominent organizations continue to rise.
Insight into the Zopiclone Business Environment
Business participants must have a complete understanding of the competitive dynamics of the global Zopiclone market to formulate their future strategy accordingly. The study outlines the corporations’ core sustainability plans as well as the effect they are expected to have on the global Zopiclone industry. The study assists competitors in capitalizing on openings in the global Zopiclonemarket while still coping with the rivalry. This will ultimately assist them in making better investment decisions and optimizing sales.
Global market drivers of Zopiclone
The production of zopiclone is projected to contribute to the growth of the global zopiclone market by leading manufacturers. For example, after the patent expiration of the Imovane (Zopiclone) brand in 2014, many players introduced generics. Besides, New Zealand is the leading consumer of prescription hypnotic drugs, according to the article of the non-profit, Best Practice Advocacy Center New Zealand in Oct 2018, and Zopiclone for insomnia is prescribed.
Insomnia is less prevalent in the Asia Pacific than in Europe and North America. According to NCBI in 2019, insomnia and those including mental conditions, such as depression, anxiety, and post-traumatic stress disorder in geriatric communities, is struggling. Co-morbid health conditions, such as restless leg syndrome, gastroesophageal reflux (GERD) diseases, persistent pain, and drug addiction may also lead to insomnia, according to the same source.
Global Market Players of Zopiclone
The major vendors in the global zopiclone industry are
• Dr. Reddy’s Pharmaceutical Industries AG Ltd.
• Glenmark Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Mylan N.V.
• Macleods Pharmaceutical Ltd.
• AVkare Inc.